当前位置: 首页 >> 检索结果
121. 2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial.
作者: Zachary T Yoneda.;Matthew O'Neill.;Diane M Crawford.;Mingfang Ao.;Lili Sun.;Majd A El-Harasis.;Lisa Pitchford.;John A Rathmacher.;Jay Montgomery.;Sharon T Shen.;Juan Carlos Estrada.;Pablo J Saavedra.;Christopher R Ellis.;Travis Richardson.;Arvindh Kangasundram.;George H Crossley.;Wendall S Akers.;Fei Ye.;Dan M Roden.;Gregory F Michaud.;M Benjamin Shoemaker.
来源: Circ Arrhythm Electrophysiol. 2025年18卷8期e013378页
Inflammation is a common mechanism for atrial fibrillation (AF). 2-Hydroxybenzylamine (2-HOBA) is a novel therapeutic that scavenges isolevuglandins-a downstream mediator of inflammation and oxidative stress. 2-HOBA is safe and reduces AF in mice, prompting a first-in-human pilot clinical trial.
122. Machine Learning Identification of Athlete Sport Type Through ECG Analysis.
作者: Lucas B Cofer.;Timothy W Churchill.;Rishi Bhuptani.;Aditya Inampudi.;Manav Rajvanshi.;Bjarni Atlason.;Simon S Y Shim.;Shaan Khurshid.;Eugene H Chung.;Aaron Baggish.;J Sawalla Guseh.;Kichang Lee.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷8期e013677页 123. Reported Incidence of Atrial Fibrillation Varies by Ethnicity and Presentation in the Multi-Ethnic Study of Atherosclerosis.
作者: Benjamin Y Hsieh.;Ting-Wei Ernie Liao.;David T Linker.
来源: Circ Arrhythm Electrophysiol. 2025年18卷8期e013620页
Atrial fibrillation (AF) is a common cardiac arrhythmia. Its detection rates vary significantly across ethnic groups, impacting epidemiological and clinical outcomes. We aim to explore ethnic differences in self-reported versus hospital-reported AF using the MESA (Multi-Ethnic Study of Atherosclerosis).
124. Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial.
作者: Sheri J Hartman.;Andrea Z LaCroix.;Dorothy D Sears.;Loki Natarajan.;Rong W Zablocki.;Ruohui Chen.;Jeffrey S Patterson.;Lindsay Dillon.;James F Sallis.;Simon Schenk.;David W Dunstan.;Neville Owen.;Dori E Rosenberg.
来源: Circulation. 2025年152卷8期492-504页
Public health and clinical guidelines identify the importance of sedentary behaviors for cardiovascular diseases, particularly among postmenopausal women. The goal of this trial was to compare the behavioral and physiological impacts of 2 distinct approaches to changing sedentary behaviors.
125. Lowering Cardiac Branched-Chain Keto Acid Levels Enhances Cardiac Glucose Oxidation and Cardiac Efficiency via Enhancing Mitochondrial Insulin Signaling in Heart Failure.
作者: Qutuba G Karwi.;Liyan Zhang.;Keshav Gopal.;Cory S Wagg.;Kim L Ho.;Qiuyu Sun.;Sai Panidarapu.;Kaya Persad.;Betüol Altuany.;Shaden Damen.;Ezra Ketema.;Jody Levasseur.;Thomas Pulinilkunnil.;John R Ussher.;Jason R B Dyck.;Gary D Lopaschuk.
来源: Circ Heart Fail. 2025年e012012页
Elevated levels of cardiac branched-chain amino acids (BCAAs) and their metabolites, namely branched-chain keto acids (BCKAs), contribute to the development of insulin resistance, contractile dysfunction, and adverse remodeling in the failing heart. However, there is still confusion about whether BCAA or BCKA mediate these detrimental effects in the failing heart.
126. Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.
作者: Jinxi Wang.;Daniela Sarahi Yang Bennett.;Emma J Echard.;Biyi Chen.;Grace Ciampa.;Weiyang Zhao.;Qian Shi.;Jin-Young Yoon.;Robert M Weiss.;Chad E Grueter.;Duane D Hall.;Barry London.;Long-Sheng Song.
来源: Circulation. 2025年
Calcium (Ca2+) homeostasis in cardiac fibroblasts (CFs) plays a critical role in myocardial repair and remodeling after injury. JPH (junctophilin-2; human JPH2 or mouse Jph2) is a structural protein known to regulate intracellular Ca2+ signaling and excitation-contraction coupling in cardiomyocytes. However, the role of JPH2 in CF biology remains unexplored.
127. Device-Measured Sleep Characteristics, Daily Step Count, and Cardiometabolic Health Markers: Findings From the Prospective Physical Activity, Sitting, and Sleep (ProPASS) Consortium.
作者: Wenxin Bian.;Matthew N Ahmadi.;Raaj Kishore Biswas.;Joanna M Blodgett.;Andrew J Atkin.;Hsiu-Wen Chan.;Borja Del Pozo Cruz.;Kristin Suorsa.;Esmée A Bakker.;Richard M Pulsford.;Gregore I Mielke.;Peter J Johansson.;Pasan Hettiarachchi.;Nicholas A Koemel.;Dick H J Thijssen.;Sari Stenholm.;Gita D Mishra.;Armando Teixeira-Pinto.;Vegar Rangul.;Lauren B Sherar.;Ulf Ekelund.;Alun D Hughes.;I-Min Lee.;Peter A Cistulli.;Andreas Holtermann.;Annemarie Koster.;Mark Hamer.;Emmanuel Stamatakis.; .
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷8期e011873页
Sleep and physical activity (PA) are important lifestyle-related behaviors that impact cardiometabolic health. This study investigated the joint associations of daily step count and sleep patterns (regularity and duration) with cardiometabolic biomarkers in adults.
128. Risk for Heart Failure and Atrial Fibrillation Across the Lifespan for Carriers of the Amyloidogenic p.V142I TTR Variant.
作者: Justin L Grodin.;Anand Gupta.;Ishan Rison.;Julia Kozlitina.;Lorena Saelices-Gomez.;Saket Girotra.;Amil M Shah.;Lori R Roth.;Jan M Griffin.;Mark H Drazner.;W H Wilson Tang.;Mathew S Maurer.;James A de Lemos.
来源: Circ Genom Precis Med. 2025年18卷4期e004911页
To better define the importance of the amyloidogenic p.V142I TTR allele across the life span of a carrier, we leveraged data from All of Us to provide a generalizable assessment of the population-level burden of cardiovascular risk and estimate the age at disease onset.
137. Lung Single-Cell Transcriptomics Reveal Diverging Pathobiology and Opportunities for Precision Targeting in Scleroderma-Associated Versus Idiopathic Pulmonary Arterial Hypertension.
作者: Tijana Tuhy.;Julie C Coursen.;Tammy Graves.;Michael Patatanian.;Christopher Cherry.;Shannon E Niedermeyer.;Sarah L Khan.;Darin T Rosen.;Michael P Croglio.;Mohab Elnashar.;Todd M Kolb.;Stephen C Mathai.;Rachel L Damico.;Paul M Hassoun.;Larissa A Shimoda.;Karthik Suresh.;Micheala A Aldred.;Catherine E Simpson.
来源: Circ Genom Precis Med. 2025年18卷4期e004936页
Pulmonary arterial hypertension (PAH) involves progressive cellular and molecular change within the pulmonary vasculature, leading to increased vascular resistance. Current therapies targeting nitric oxide, endothelin, and prostacyclin pathways yield variable treatment responses. Patients with systemic sclerosis-associated PAH (SSc-PAH) often experience worse outcomes than those with idiopathic PAH (IPAH). We hypothesized that distinct and overlapping gene expression patterns in SSc-PAH versus IPAH lung tissues could inform the investigation of precision-targeted therapies.
138. Association of Smoking Cannabis With Cardiovascular Events Among Veterans With Coronary Artery Disease.
作者: Salomeh Keyhani.;Beth E Cohen.;Marzieh Vali.;Katherine J Hoggatt.;Dawn M Bravata.;Peter C Austin.;Emily Lum.;Deborah Hasin.;Carl Grunfeld.;Michael G Shlipak.
来源: Circulation. 2025年152卷6期352-365页
Whether cannabis is a risk factor for cardiovascular events is unknown. We examined the association between smoking cannabis and cardiovascular events in a cohort of older veterans (66 to 68 years of age) with coronary artery disease.
139. Calibrated Functional Data Decrease Clinical Uncertainty for KCNH2-Related Long-QT Syndrome.
作者: Chai-Ann Ng.;Matthew J O'Neill.;Samskruthi R Padigepati.;Yi-Lee Ting.;Flavia M Facio.;Matteo Vatta.;Sarah R Poll.;Jason A Reuter.;Jamie I Vandenberg.;Brett M Kroncke.
来源: Circ Genom Precis Med. 2025年18卷4期e005204页 140. VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction.
作者: Zhongxiang Chen.;Diqi Zhu.;Kaa Seng Lai.;Yiwei Chen.;Yuqing Hu.;Yabo Fang.;Zihang Yan.;Beibei Hu.;Zhen Zhang.;Min Zhang.;Fen Li.
来源: Circ Genom Precis Med. 2025年18卷4期e004879页
A sustained dosage of VEGFA (vascular endothelial growth factor A) is crucial for angiogenesis in both homeostasis and cardiovascular diseases. Start codon CUG-initiated alternative translation is a conserved mechanism for producing mature VEGFA. Genetic surveys have identified stop-gained variants predicted to prematurely terminate CUG-initiated translation without affecting start codon ATG-initiated translation. However, the impacts of these variants on the vasculature in steady-state and disease conditions remain unknown.
|